Document Detail

HIV-HCV co-infection: epidemiology, pathogenesis and therapeutic implications.
MedLine Citation:
PMID:  23111959     Owner:  NLM     Status:  In-Data-Review    
Hepatitis C virus (HCV) is the cause of more than three-quarters of liver-related deaths in HIV-seropositive individuals and it is remarkable that today approximately one-quarter of HIV-infected individuals in Europe and the USA have a HCV coinfection. HIV/HCV coinfected patients were more likely to develop cirrhosis, had an increased risk of developing AIDS, of HIV-related disease and of overall mortality. How HCV may affect the course of HIV infection is not well known even if it was suggested that HCV co-infection is able to increase immune activation and to sensitize CD4+ T-cells towards apoptosis in the absence of HIV therapy. There are many evidences that the simultaneous presence of HIV infection accelerates the liver damage from HCV favouring the evolution to cirrhosis in co-infected patients. HIV increasing of TNF alpha liver production and of HCV replication in peripheral blood lymphomonocytes are the mechanisms at the basis of this phenomenon. HAART had a positive effect on HIV/HCV co-infection, otherwise it does not appear to fully correct the adverse effect of HIV infection on HCV-related outcomes. Traditional treatment with pegilated Interferon plus ribavirin have low rates of sustained virological response in co-infected patients especially if infected with HCV genotype 1, and better results were often obtained in patients in which the use of antiretroviral treatment was avoided to reduce the occurrence of adverse effects. The recent preliminary results on the use of anti-HCV protease inhibitor drugs, boceprevir and telapravir, in co-infected people seems to demonstrate an enhanced antiviral efficacy in the HIV/HCV co-infected population of triple anti-HCV treatment even is some important limitation as interactions with antiretroviral agents and selection of HCV drug resistance, lead to consider the need for further studies designed to assess the best therapeutic strategies.
M Andreoni; A Giacometti; I Maida; P Meraviglia; D Ripamonti; L Sarmati
Related Documents :
24968599 - Myelodysplasia in ugandan patients with hiv/aids: an autopsy study.
23130709 - Non-neutralizing antibodies in prevention of hiv infection.
23506949 - Glycodendrimers as new tools in the search for effective anti-hiv dc-based immunotherap...
23703729 - Epigenetic regulation of microrna-122 by peroxisome proliferator activated receptor-gam...
23845899 - Fetal bovine serum inhibits hepatitis c virus attachment to host cells.
24812479 - Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus...
12558359 - Hepatitis c in the hiv-infected person.
8918079 - Treatment of chronic hepatitis c with interferon-alpha: a preliminary report.
23323249 - Hepatitis c virus and hepatocarcinogenesis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  16     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1473-83     Citation Subset:  IM    
Clinical Infectious Diseases, Tor Vergata University, Rome, Italy. Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy Clinical Infectious Diseases, Sassari University, Sassari, Italy Second department Infectious Diseases Division, Sacco Hospital, Milano, Italy Ospedali Riuniti di Bergamo, Bergamo, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  High reinfection rate of Helicobacter pylori in young type 1 diabetic patients: a three-year follow-...
Next Document:  Boswellia serrata and Salvia miltiorrhiza extracts reduce DMN-induced hepatic fibrosis in mice by TG...